{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:35:06Z","timestamp":1792852506257,"version":"4.5.0"},"reference-count":70,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec id=\"ab-yoi250005-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Bariatric surgery, once the criterion standard in obesity treatment, has a small but concerning association with increased suicidality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), originally developed to treat diabetes, now provide substantial efficacy in the treatment of obesity. However, concerns of risk of suicidality with these medicines have been raised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250005-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the risk of suicidality and self-harm in randomized, placebo-controlled trials of GLP-1 RAs in adults with diabetes or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250005-6\">\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>MEDLINE, Embase, ClinicalTrials.gov, and Cochrane databases were systematically searched from inception to August 29, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250005-7\">\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Reports of randomized clinical trials (RCTs) lasting 6 or more months comparing GLP-1 RAs with placebo for the treatment of diabetes or obesity published in peer-reviewed journals were identified. Two independent reviewers screened all search-identified studies for inclusion. Records of outcomes were queried from primary papers, ClinicalTrials.gov entries, and corresponding authors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250005-8\">\n                    <jats:title>Data Extraction and Synthesis<\/jats:title>\n                    <jats:p>Two independent researchers abstracted data and assessed data quality and validity using PRISMA guidelines. Data were pooled using random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250005-9\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Pooled incidence of completed or attempted suicide, occurrences of suicidal ideation, or self-harm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250005-10\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 27 of 144 RCTs meeting inclusion criteria systematically recorded suicide and\/or self-harm-related events and included 32\u202f354 individuals receiving GLP-1 RAs and 27\u202f042 treated with placebo, over 69 653 and 63 853\u2009 person-years of exposure, respectively. Event incidence was very low in the GLP-1 RA (0.047 per 100 person-years) and placebo (0.042 per 100 person-years) groups, with no statistically significant difference (rate ratio [RR], 0.76; 95% CI, 0.48-1.21;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.25). Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 RA used. Five studies were considered at risk of bias due to the loss of more than 5% of participants to follow-up. Otherwise, studies were not found to be heterogeneous nor at high risk of bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-yoi250005-11\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 RAs within the context of RCTs. While these findings may further ease concerns about these adverse effects, continued monitoring is warranted to identify particular patients who may be at risk as extended use of GLP-1 RAs expands.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.0091","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:35:39Z","timestamp":1742384139000},"page":"888","source":"Crossref","is-referenced-by-count":52,"title":["Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity"],"prefix":"10.1001","volume":"82","author":[{"given":"Pouya","family":"Ebrahimi","sequence":"first","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Batlle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Ayati","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Haisum","family":"Maqsood","sequence":"additional","affiliation":[{"name":"Department of Cardiology, DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarine","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Tarabanis","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"McGowan","sequence":"additional","affiliation":[{"name":"Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York"},{"name":"New York University Center for the Prevention of Cardiovascular Disease, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Liebers","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Laynor","sequence":"additional","affiliation":[{"name":"Medical Library, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Heffron","sequence":"additional","affiliation":[{"name":"Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York"},{"name":"New York University Center for the Prevention of Cardiovascular Disease, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"yoi250005r1","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials.","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"24","key":"yoi250005r2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"38","key":"yoi250005r3","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement.","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur Heart J"},{"issue":"2","key":"yoi250005r4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/SLA.0000000000003742","article-title":"Prediction of suicide and nonfatal self-harm after bariatric surgery: a risk score based on sociodemographic factors, lifestyle behavior, and mental health: a nonrandomized controlled trial.","volume":"274","author":"Konttinen","year":"2021","journal-title":"Ann Surg"},{"issue":"5","key":"yoi250005r5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/obr.12014","article-title":"Risk of completed suicide after bariatric surgery: a systematic review.","volume":"14","author":"Peterh\u00e4nsel","year":"2013","journal-title":"Obes Rev"},{"issue":"4","key":"yoi250005r6","doi-asserted-by":"publisher","first-page":"e760","DOI":"10.1097\/SLA.0000000000005825","article-title":"Bariatric surgery and suicide risk in patients with obesity.","volume":"278","author":"Hung","year":"2023","journal-title":"Ann Surg"},{"issue":"4","key":"yoi250005r7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/oby.20066","article-title":"Possible risk factors for increased suicide following bariatric surgery.","volume":"21","author":"Mitchell","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"yoi250005r8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11695-018-3493-4","article-title":"Risk of suicide and self-harm is increased after bariatric surgery-a systematic review and meta-analysis.","volume":"29","author":"Castaneda","year":"2019","journal-title":"Obes Surg"},{"issue":"1","key":"yoi250005r9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"yoi250005r10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/14740338.2024.2335215","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas.","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"yoi250005r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23335","article-title":"GLP-1 receptor agonists and suicidality-caution is needed.","volume":"7","author":"Salvo","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"yoi250005r12","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2023.2474","article-title":"Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.","volume":"66","author":"Chen","year":"2023","journal-title":"Eur Psychiatry"},{"issue":"11","key":"yoi250005r13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials.","volume":"19","author":"O\u2019Neil","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"yoi250005r14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort.","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"yoi250005r15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 receptor agonist use and risk of suicide death.","volume":"184","author":"Ueda","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"11","key":"yoi250005r16","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1111\/dom.15864","article-title":"Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: a comprehensive analysis of the global pharmacovigilance database.","volume":"26","author":"Kim","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"yoi250005r17","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/dom.15538","article-title":"Glucagon-like peptide-1 receptor agonists and mental health: a meta-analysis of randomized controlled trials.","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"yoi250005r19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"yoi250005r22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"yoi250005r23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis.","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"issue":"7414","key":"yoi250005r24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"yoi250005r25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MNH.0000000000000976","article-title":"Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.","volume":"33","author":"Holliday","year":"2024","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"12","key":"yoi250005r26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity.","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"yoi250005r28","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials.","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"7","key":"yoi250005r30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012990.pub2","article-title":"GLP-1 receptor agonists for Parkinson\u2019s disease.","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"yoi250005r31","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease.","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"yoi250005r32","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.2024.1017","article-title":"Could GLP-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions?","volume":"331","author":"Rubin","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"yoi250005r33","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"yoi250005r34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32610","article-title":"Efficacy of semaglutide in treating obesity: a systematic review of randomized controlled trials (RCTs).","volume":"14","author":"Anam","year":"2022","journal-title":"Cureus"},{"key":"yoi250005r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"22","key":"yoi250005r36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation.","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"yoi250005r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100080","article-title":"Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study.","volume":"7","author":"Richards","year":"2023","journal-title":"Obes Pillars"},{"issue":"1","key":"yoi250005r38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11481-024-10142-w","article-title":"Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes mellitus mouse model via the microbiota-gut-brain axis.","volume":"19","author":"de Paiva","year":"2024","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"yoi250005r39","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial.","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"yoi250005r40","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/bjs.10258","article-title":"Alcohol and substance abuse, depression and suicide attempts after Roux-en-Y gastric bypass surgery.","volume":"103","author":"Backman","year":"2016","journal-title":"Br J Surg"},{"issue":"10077","key":"yoi250005r41","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"yoi250005r42","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2337\/dc14-0024","article-title":"HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.","volume":"37","author":"Ahr\u00e9n","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"yoi250005r43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"yoi250005r44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"issue":"10103","key":"yoi250005r45","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial.","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"yoi250005r46","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0?mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial.","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"yoi250005r47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"issue":"7","key":"yoi250005r48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial.","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"10278","key":"yoi250005r49","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"yoi250005r50","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.2337\/dc21-2656","article-title":"Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial.","volume":"45","author":"Frias","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"yoi250005r51","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial.","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"issue":"10193","key":"yoi250005r52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10157","key":"yoi250005r53","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"13","key":"yoi250005r54","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"yoi250005r55","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2337\/dc13-2855","article-title":"Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.","volume":"37","author":"Leiter","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"yoi250005r56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"yoi250005r57","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial.","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"12","key":"yoi250005r58","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"yoi250005r59","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"yoi250005r60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled trial of 3.0 mg of liraglutide in weight management.","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"yoi250005r61","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa149","article-title":"Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes.","volume":"105","author":"Pozzilli","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"yoi250005r62","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/dom.12382","article-title":"Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.","volume":"16","author":"Reusch","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"yoi250005r63","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/dom.14566","article-title":"Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: a randomized clinical trial in primary care (LIRA-PRIME).","volume":"24","author":"Unger","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"yoi250005r64","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of \u00df-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"9","author":"von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"yoi250005r65","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"yoi250005r66","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"ILiraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial.","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"14","key":"yoi250005r67","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"yoi250005r68","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"yoi250005r69","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"12","key":"yoi250005r70","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"yoi250005r18","unstructured":"PROSPERO. Suicide and self-harm with GLP-1 receptor agonists\u2014a systematic review and meta-analysis. 2023. Accessed February 14, 2025. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023399654"},{"key":"yoi250005r20","unstructured":"Cochrane Training. Cochrane handbook for systematic reviews of interventions version 6.5. 2024. Accessed September 19, 2024. http:\/\/www.training.cochrane.org\/handbook"},{"key":"yoi250005r21","unstructured":"Veritas Health Innovation. Covidence systematic review software. Accessed March 25, 2023. http:\/\/www.covidence.org."},{"key":"yoi250005r27","unstructured":"US Centers for Disease Control National Center for Health Statistics. Suicide among adults age 55 and older, 2021. NCHS Data Brief No. 483. November 2023. Accessed February 14, 2025. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db483.htm"},{"key":"yoi250005r29","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda. 2023. Accessed February 14, 2025. https:\/\/www.ema.europa.eu\/en\/committees\/pharmacovigilance-risk-assessment-committee-prac"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2831637\/jamapsychiatry_ebrahimi_2025_oi_250005_1755883049.22309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:01:01Z","timestamp":1756911661000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2831637"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0091","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}